| Year |
Citation |
Score |
| 2024 |
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2301214. PMID 38301187 DOI: 10.1200/JCO.23.01214 |
0.323 |
|
| 2024 |
Saldajeno DP, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga RM, Tamura N, Aruga T, Ikeda K, Fukui Y, Maeshima Y, ... ... Toi M, et al. Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients. British Journal of Cancer. PMID 38238427 DOI: 10.1038/s41416-023-02527-0 |
0.479 |
|
| 2024 |
Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Kinukawa N, Watanabe C, Toi M, Saji S. 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan. Breast Cancer (Tokyo, Japan). PMID 38180641 DOI: 10.1007/s12282-023-01532-8 |
0.428 |
|
| 2023 |
Costa L, Kumar R, Villarreal-Garza C, Sinha S, Saini S, Semwal J, Saxsena V, Zamre V, Chintamani C, Ray M, Shimizu C, Gusic LH, Toi M, Lipton A. Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers. Breast (Edinburgh, Scotland). 73: 103623. PMID 38219460 DOI: 10.1016/j.breast.2023.103623 |
0.354 |
|
| 2023 |
Yamaguchi A, Kawaguchi K, Kawanishi K, Maeshima Y, Nakakura A, Kataoka TR, Takahara S, Nakagawa S, Yonezawa A, Takada M, Kawashima M, Kawaguchi-Sakita N, Kotake T, Suzuki E, Shimizu H, ... ... Toi M, et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Research and Treatment. PMID 38123790 DOI: 10.1007/s10549-023-07163-z |
0.42 |
|
| 2023 |
Miyashita M, Kumamaru H, Niikura N, Sagara Y, Konishi T, Iwamoto T, Sanuki N, Tanakura K, Nagahashi M, Hayashi N, Yoshida M, Watanabe C, Kinukawa N, Toi M, Saji S. Annual report of the Japanese Breast Cancer Registry for 2019. Breast Cancer (Tokyo, Japan). PMID 38044372 DOI: 10.1007/s12282-023-01526-6 |
0.431 |
|
| 2023 |
García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, Mc Carthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, et al. Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE study. European Journal of Cancer (Oxford, England : 1990). 196: 113420. PMID 38000218 DOI: 10.1016/j.ejca.2023.113420 |
0.361 |
|
| 2023 |
Li W, Kawaguchi K, Tanaka S, He C, Maeshima Y, Suzuki E, Toi M. Cellular senescence triggers intracellular acidification and lysosomal pH alkalinized via ATP6AP2 attenuation in breast cancer cells. Communications Biology. 6: 1147. PMID 37993606 DOI: 10.1038/s42003-023-05433-6 |
0.425 |
|
| 2023 |
Nishikawa Y, Agatsuma N, Utsumi T, Funakoshi T, Mori Y, Nakamura Y, Hoshino N, Horimatsu T, Saito T, Kashihara S, Fukuyoshi J, Goto R, Toi M, Takahashi Y, Nakayama T. Medical care costs according to the stage and subtype of breast cancer in a municipal setting: a case study of Hachioji City, Japan. Breast Cancer (Tokyo, Japan). PMID 37982959 DOI: 10.1007/s12282-023-01517-7 |
0.359 |
|
| 2023 |
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martín M. Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37889120 DOI: 10.1158/1078-0432.CCR-22-3573 |
0.36 |
|
| 2023 |
Kuo SH, Tseng LM, Chen ST, Sagara Y, Chang YC, Yeh HT, Kuo YL, Hung CC, Lu TP, Lee YH, Toi M, Huang CS. Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial). Bmc Cancer. 23: 865. PMID 37710198 DOI: 10.1186/s12885-023-11291-6 |
0.392 |
|
| 2023 |
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, ... ... Toi M, et al. A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer. Breast Cancer Research and Treatment. 202: 485-496. PMID 37676450 DOI: 10.1007/s10549-023-07099-4 |
0.385 |
|
| 2023 |
Toi M, Aruga T. SERDs for primary breast cancer. The Lancet. Oncology. 24: 947-949. PMID 37657466 DOI: 10.1016/S1470-2045(23)00291-7 |
0.501 |
|
| 2023 |
Liu L, Kawashima M, Sugimoto M, Sonomura K, Pu F, Li W, Takeda M, Goto T, Kawaguchi K, Sato TA, Toi M. Discovery of lipid profiles in plasma-derived extracellular vesicles as biomarkers for breast cancer diagnosis. Cancer Science. PMID 37608343 DOI: 10.1111/cas.15935 |
0.453 |
|
| 2023 |
Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, ... ... Toi M, et al. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06). Cancer Medicine. PMID 37525895 DOI: 10.1002/cam4.6390 |
0.372 |
|
| 2023 |
Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, Chigusa Y, Kawai M, Sawada M, Inoue T, Takeuchi Y, Maeda H, Baba S, Shiozawa Y, Saiki R, ... ... Toi M, et al. Evolutionary histories of breast cancer and related clones. Nature. PMID 37495687 DOI: 10.1038/s41586-023-06333-9 |
0.448 |
|
| 2023 |
Kobayashi K, Masuda N, Mizuno T, Miura K, Tokuda Y, Yoshinami T, Kawaguchi H, Ohtani S, Saeki T, Toi M, Takeuchi M, Ito Y. Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03). Breast Cancer Research and Treatment. PMID 37480384 DOI: 10.1007/s10549-023-07030-x |
0.422 |
|
| 2023 |
Adachi Y, Asaga S, Kumamaru H, Kinugawa N, Sagara Y, Niikura N, Jinno H, Saji S, Toi M. Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry. Breast Cancer Research and Treatment. PMID 37479943 DOI: 10.1007/s10549-023-07022-x |
0.309 |
|
| 2023 |
Ohashi A, Kataoka M, Iima M, Honda M, Ota R, Urushibata Y, Dominik Nickel M, Toi M, Zackrisson S, Nakamoto Y. A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI. European Radiology. PMID 37286791 DOI: 10.1007/s00330-023-09730-w |
0.46 |
|
| 2023 |
Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Torii M, Yakami M, Isoda H, Takakura K, Morita S, Takada M, Toi M, Nakamoto Y. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound. Annals of Nuclear Medicine. PMID 37280410 DOI: 10.1007/s12149-023-01846-9 |
0.448 |
|
| 2023 |
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine. 388: 2058-2070. PMID 37256976 DOI: 10.1056/NEJMoa2214131 |
0.394 |
|
| 2023 |
Yamada Y, Simon R, Iwane K, Nakanishi Y, Takeuchi Y, Yoshizawa A, Takada M, Toi M, Haga H, Marx A, Sauter G. An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9. Bmc Cancer. 23: 438. PMID 37179317 DOI: 10.1186/s12885-023-10949-5 |
0.513 |
|
| 2023 |
Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer C, Tutt A. Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast Cancer (Tokyo, Japan). PMID 37171785 DOI: 10.1007/s12282-023-01468-z |
0.388 |
|
| 2023 |
He C, Konishi R, Harata A, Nakamura Y, Mizuno R, Yoda M, Toi M, Kawaguchi K, Kawaoka S. Serum amyloid alpha 1-2 are not required for liver inflammation in the 4T1 murine breast cancer model. Frontiers in Immunology. 14: 1097788. PMID 36817472 DOI: 10.3389/fimmu.2023.1097788 |
0.355 |
|
| 2023 |
Vandenbon A, Mizuno R, Konishi R, Onishi M, Masuda K, Kobayashi Y, Kawamoto H, Suzuki A, He C, Nakamura Y, Kawaguchi K, Toi M, Shimizu M, Tanaka Y, Suzuki Y, et al. Murine breast cancers disorganize the liver transcriptome in a zonated manner. Communications Biology. 6: 97. PMID 36694005 DOI: 10.1038/s42003-023-04479-w |
0.365 |
|
| 2023 |
Imoto S, Wang K, Bi XW, Liu G, Im YH, Im SA, Sim SH, Ueno T, Futamura M, Toi M, Fujiwara Y, Ahn SG, Lee JE, Park YH, Takao S, et al. Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast Cancer (Tokyo, Japan). PMID 36689066 DOI: 10.1007/s12282-023-01436-7 |
0.389 |
|
| 2022 |
Nakayama Y, Hanada M, Koda H, Sugimoto M, Takada M, Toi M. Breast cancer detection using volatile compound profiles in exhaled breath via selected ion-flow tube mass spectrometry. Journal of Breath Research. 17. PMID 36541460 DOI: 10.1088/1752-7163/aca696 |
0.344 |
|
| 2022 |
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study. Japanese Journal of Clinical Oncology. PMID 36484305 DOI: 10.1093/jjco/hyac184 |
0.322 |
|
| 2022 |
Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Fujimoto K, Sugie T, Toi M, Nakamoto Y. Reproducibility assessment of uptake on dedicated breast PET for noise discrimination. Annals of Nuclear Medicine. PMID 36434200 DOI: 10.1007/s12149-022-01809-6 |
0.328 |
|
| 2022 |
Mori T, Okamoto Y, Mu A, Ide Y, Yoshimura A, Senda N, Inagaki-Kawata Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, ... ... Toi M, et al. Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers. Cancer Medicine. PMID 36345163 DOI: 10.1002/cam4.5430 |
0.386 |
|
| 2022 |
Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, Wei R, Sapunar F, Grimes BR, Nabinger SC, Johnston SRD. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1. The Oncologist. PMID 36342342 DOI: 10.1093/oncolo/oyac234 |
0.411 |
|
| 2022 |
Kawaguchi K, Maeshima Y, Toi M. Tumor immune microenvironment and systemic response in breast cancer. Medical Oncology (Northwood, London, England). 39: 208. PMID 36175677 DOI: 10.1007/s12032-022-01782-0 |
0.366 |
|
| 2022 |
Toi M, Huang CS, Im YH, Sohn J, Zhang W, Sakaguchi S, Haddad N, van Hal G, Sledge GW. Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall Survival from MONARCH 2. Cancer Science. PMID 36168844 DOI: 10.1111/cas.15600 |
0.349 |
|
| 2022 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawaguchi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. PMID 36166110 DOI: 10.1007/s10147-022-02237-2 |
0.409 |
|
| 2022 |
Galactionova K, Loibl S, Salari P, Marmé F, Martin M, Untch M, Bonnefoi HR, Kim SB, Bear HD, McCarthy N, Gelmon KA, García-Sáenz JA, Kelly CM, Reimer T, Toi M, et al. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial. Frontiers in Oncology. 12: 886831. PMID 36132153 DOI: 10.3389/fonc.2022.886831 |
0.361 |
|
| 2022 |
Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies. Breast Cancer (Tokyo, Japan). PMID 36057014 DOI: 10.1007/s12282-022-01399-1 |
0.397 |
|
| 2022 |
Honda M, Iima M, Kataoka M, Fukushima Y, Ota R, Ohashi A, Toi M, Nakamoto Y. Biomarkers Predictive of Distant Disease-free Survival Derived from Diffusion-weighted Imaging of Breast Cancer. Magnetic Resonance in Medical Sciences : Mrms : An Official Journal of Japan Society of Magnetic Resonance in Medicine. PMID 35922924 DOI: 10.2463/mrms.mp.2022-0060 |
0.375 |
|
| 2022 |
Velaga R, Tanaka S, Toi M. Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours. Cancer Drug Resistance (Alhambra, Calif.). 5: 487-497. PMID 35800379 DOI: 10.20517/cdr.2022.10 |
0.45 |
|
| 2022 |
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, ... ... Toi M, et al. Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS). Cancer Science. PMID 35754298 DOI: 10.1111/cas.15474 |
0.414 |
|
| 2022 |
Paul AM, George B, Saini S, Pillai MR, Toi M, Costa L, Kumar R. Delineation of Pathogenomic Insights of Breast Cancer in Young Women. Cells. 11. PMID 35741056 DOI: 10.3390/cells11121927 |
0.41 |
|
| 2022 |
Honda M, Kataoka M, Iima M, Ota R, Ohashi A, Kishimoto AO, Miyake KK, Nickel MD, Yamada Y, Toi M, Nakamoto Y. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer after Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography (Ann Arbor, Mich.). 8: 1522-1533. PMID 35736873 DOI: 10.3390/tomography8030125 |
0.415 |
|
| 2022 |
Kumar R, Abreu C, Toi M, Saini S, Casimiro S, Arora A, Paul AM, Velaga R, Rameshwar P, Lipton A, Gupta S, Costa L. Oncobiology and treatment of breast cancer in young women. Cancer Metastasis Reviews. PMID 35488982 DOI: 10.1007/s10555-022-10034-6 |
0.438 |
|
| 2022 |
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, ... ... Toi M, et al. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. Bmc Medicine. 20: 136. PMID 35462552 DOI: 10.1186/s12916-022-02332-1 |
0.445 |
|
| 2022 |
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, ... ... Toi M, et al. Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study. Breast Cancer (Tokyo, Japan). PMID 35460066 DOI: 10.1007/s12282-022-01357-x |
0.387 |
|
| 2022 |
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, ... ... Toi M, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. The Lancet. Oncology. 23: 636-649. PMID 35405087 DOI: 10.1016/S1470-2045(22)00196-6 |
0.403 |
|
| 2022 |
Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. Cancer Management and Research. 14: 1179-1194. PMID 35342308 DOI: 10.2147/CMAR.S348591 |
0.406 |
|
| 2022 |
van Mackelenbergh MT, Seither F, Möbus V, O'Shaughnessy J, Martin M, Joensuu H, Untch M, Nitz U, Steger GG, Miralles JJ, Barrios CH, Toi M, Bear HD, Muss H, Reimer T, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer (Oxford, England : 1990). 166: 185-201. PMID 35305453 DOI: 10.1016/j.ejca.2022.02.003 |
0.359 |
|
| 2022 |
Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, ... ... Toi M, et al. Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. Japanese Journal of Clinical Oncology. PMID 35296894 DOI: 10.1093/jjco/hyac022 |
0.352 |
|
| 2022 |
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Clinical Significance of and Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35121623 DOI: 10.1158/1078-0432.CCR-21-3276 |
0.352 |
|
| 2021 |
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100896. PMID 34890214 DOI: 10.1200/JCO.21.00896 |
0.378 |
|
| 2021 |
Masuda N, Kosaka N, Iwata H, Toi M. Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data. International Journal of Clinical Oncology. 26: 2179-2193. PMID 34698970 DOI: 10.1007/s10147-021-02013-8 |
0.426 |
|
| 2021 |
Yotsumoto D, Sagara Y, Kumamaru H, Niikura N, Miyata H, Kanbayashi C, Tsuda H, Yamamoto Y, Aogi K, Kubo M, Tamura K, Hayashi N, Miyashita M, Kadoya T, Saji S, ... Toi M, et al. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan. Breast Cancer (Tokyo, Japan). PMID 34665435 DOI: 10.1007/s12282-021-01307-z |
0.396 |
|
| 2021 |
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 34661821 DOI: 10.1007/s12282-021-01295-0 |
0.393 |
|
| 2021 |
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, Matsunami N, Mashino K, Kosaka T, Tanabe M, Yotsumoto D, Yamanouchi K, Sawaki M, Kashiwaba M, Kawabata H, ... ... Toi M, et al. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17). Breast Cancer Research and Treatment. PMID 34554370 DOI: 10.1007/s10549-021-06396-0 |
0.398 |
|
| 2021 |
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. Breast Cancer Research : Bcr. 23: 87. PMID 34425869 DOI: 10.1186/s13058-021-01463-2 |
0.308 |
|
| 2021 |
Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, et al. MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34376533 DOI: 10.1158/1078-0432.CCR-20-4685 |
0.363 |
|
| 2021 |
Miyake KK, Kataoka M, Ishimori T, Matsumoto Y, Torii M, Takada M, Satoh Y, Kubota K, Satake H, Yakami M, Isoda H, Ikeda DM, Toi M, Nakamoto Y. A Proposed Dedicated Breast PET Lexicon: Standardization of Description and Reporting of Radiotracer Uptake in the Breast. Diagnostics (Basel, Switzerland). 11. PMID 34359350 DOI: 10.3390/diagnostics11071267 |
0.369 |
|
| 2021 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. PMID 34043103 DOI: 10.1007/s10147-021-01940-w |
0.409 |
|
| 2021 |
Senda N, Kawaguchi-Sakita N, Kawashima M, Inagaki-Kawata Y, Yoshida K, Takada M, Kataoka M, Torii M, Nishimura T, Kawaguchi K, Suzuki E, Kataoka Y, Matsumoto Y, Yoshibayashi H, Yamagami K, ... ... Toi M, et al. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Cancer Science. PMID 34036661 DOI: 10.1111/cas.14986 |
0.389 |
|
| 2021 |
Itou J, Nakamura A, Hokazono H, Toi M. Supplementation with Fermented Barley Extract Prevents Mammary Epithelial Cell Invasion in an Early Breast Cancer Model. Acta Histochemica Et Cytochemica. 54: 73-78. PMID 34012179 DOI: JST.JSTAGE/ahc/20-00029 |
0.443 |
|
| 2021 |
Aogi K, Watanabe K, Kitada M, Sangai T, Ohtani S, Aruga T, Kawagichi H, Fujisawa T, Maeda S, Morimoto T, Sato N, Takao S, Morita S, Masuda N, Toi M, et al. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19). International Journal of Clinical Oncology. 26: 1229-1236. PMID 33891194 DOI: 10.1007/s10147-021-01920-0 |
0.411 |
|
| 2021 |
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J, Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW, ... Toi M, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer (Tokyo, Japan). PMID 33797023 DOI: 10.1007/s12282-021-01239-8 |
0.329 |
|
| 2021 |
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Melé Olivé M, Gelmon K, García-Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003639. PMID 33793299 DOI: 10.1200/JCO.20.03639 |
0.405 |
|
| 2021 |
Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, ... ... Toi M, et al. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial. Breast Cancer Research and Treatment. PMID 33763789 DOI: 10.1007/s10549-021-06184-w |
0.447 |
|
| 2021 |
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001204. PMID 33539215 DOI: 10.1200/JCO.20.01204 |
0.356 |
|
| 2021 |
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. PMID 33392835 DOI: 10.1007/s10549-020-06029-y |
0.323 |
|
| 2021 |
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 22: 74-84. PMID 33387497 DOI: 10.1016/S1470-2045(20)30534-9 |
0.457 |
|
| 2020 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Ohtani S, Shimizu C, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. Breast Cancer (Tokyo, Japan). PMID 33085032 DOI: 10.1007/s12282-020-01162-4 |
0.33 |
|
| 2020 |
Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, ... ... Toi M, et al. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Communications Biology. 3: 578. PMID 33067557 DOI: 10.1038/s42003-020-01301-9 |
0.358 |
|
| 2020 |
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002514. PMID 32954927 DOI: 10.1200/JCO.20.02514 |
0.413 |
|
| 2020 |
Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Correction to: Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism. 8: 18. PMID 32789015 DOI: 10.1186/s40170-020-00224-7 |
0.645 |
|
| 2020 |
Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, ... ... Toi M, et al. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study. Breast Cancer (Tokyo, Japan). PMID 32715420 DOI: 10.1007/s12282-020-01138-4 |
0.415 |
|
| 2020 |
Kawashima M, Bensaad K, Zois CE, Barberis A, Bridges E, Wigfield S, Lagerholm C, Dmitriev RI, Tokiwa M, Toi M, Papkovsky DB, Buffa FM, Harris AL. Disruption of hypoxia-inducible fatty acid binding protein 7 induces beige fat-like differentiation and thermogenesis in breast cancer cells. Cancer & Metabolism. 8: 13. PMID 32647572 DOI: 10.1186/S40170-020-00219-4 |
0.642 |
|
| 2020 |
Chow LWC, Lie EF, Toi M. Advances in EGFR/HER2-directed clinical research on breast cancer. Advances in Cancer Research. 147: 375-428. PMID 32593406 DOI: 10.1016/bs.acr.2020.04.009 |
0.429 |
|
| 2020 |
Lin X, Matsumoto Y, Nakakimura T, Ono K, Umeoka S, Torii M, Yoshibayashi H, Toi M. Invasive solid papillary carcinoma with neuroendocrine differentiation of the breast: a case report and literature review. Surgical Case Reports. 6: 143. PMID 32562013 DOI: 10.1186/s40792-020-00905-x |
0.413 |
|
| 2020 |
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib Plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. The Oncologist. PMID 32536013 DOI: 10.1634/theoncologist.2020-0084 |
0.333 |
|
| 2020 |
Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chinese Clinical Oncology. 9: 32. PMID 32527117 DOI: 10.21037/cco-20-123 |
0.361 |
|
| 2020 |
Takahashi M, Masuda N, Nishimura R, Inoue K, Ohno S, Iwata H, Hashigaki S, Muramatsu Y, Umeyama Y, Toi M. Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. Cancer Medicine. PMID 32420697 DOI: 10.1002/cam4.3091 |
0.346 |
|
| 2020 |
Tanaka S, Ishii T, Sato F, Toi M, Itou J. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. Biochemical and Biophysical Research Communications. PMID 32201082 DOI: 10.1016/j.bbrc.2020.03.042 |
0.353 |
|
| 2020 |
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, Mizutani M, Ohtani S, Kaneko K, Fujisawa T, Takahashi M, Kadoya T, Matsunami N, Yamamoto Y, Ohno S, ... ... Toi M, et al. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast Cancer Research and Treatment. PMID 32170634 DOI: 10.1007/s10549-020-05590-w |
0.311 |
|
| 2020 |
Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, ... ... Toi M, et al. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer (Tokyo, Japan). PMID 32060785 DOI: 10.1007/S12282-020-01057-4 |
0.373 |
|
| 2020 |
Kaufman PA, Toi M, Neven P, Sohn J, Grischke EM, Andre V, Stoffregen C, Shekarriz S, Price GL, Carter GC, Sledge GW. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist. 25: e243-e251. PMID 32043763 DOI: 10.1634/theoncologist.2019-0551 |
0.323 |
|
| 2020 |
Itou J, Takahashi R, Sasanuma H, Tsuda M, Morimoto S, Matsumoto Y, Ishii T, Sato F, Takeda S, Toi M. Estrogen Induces Mammary Ductal Dysplasia via the Upregulation of Myc Expression in a DNA-Repair-Deficient Condition. Iscience. 23: 100821. PMID 31978754 DOI: 10.1016/j.isci.2020.100821 |
0.402 |
|
| 2020 |
Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, ... ... Toi M, et al. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Research and Treatment. PMID 31953696 DOI: 10.1007/s10549-020-05524-6 |
0.383 |
|
| 2020 |
Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Japanese Journal of Clinical Oncology. 50: 3-11. PMID 31821506 DOI: 10.1093/jjco/hyz119 |
0.308 |
|
| 2020 |
Honda M, Kataoka M, Onishi N, Iima M, Ohashi A, Kanao S, Nickel MD, Toi M, Togashi K. New parameters of ultrafast dynamic contrast-enhanced breast MRI using compressed sensing. Journal of Magnetic Resonance Imaging : Jmri. 51: 164-174. PMID 31215107 DOI: 10.1002/jmri.26838 |
0.346 |
|
| 2019 |
Shibata T, Watari K, Kawahara A, Sudo T, Hattori S, Murakami Y, Izumi H, Itou J, Toi M, Akiba J, Akagi Y, Tanaka M, Kuwano M, Ono M. Targeting phosphorylation of Y-box binding protein YBX1 by TAS0612 and everolimus in overcoming antiestrogen resistance. Molecular Cancer Therapeutics. PMID 31879363 DOI: 10.1158/1535-7163.MCT-19-0690 |
0.395 |
|
| 2019 |
Kawashima M, Tokiwa M, Nishimura T, Kawata Y, Sugimoto M, Kataoka TR, Sakurai T, Iwaisako K, Suzuki E, Hagiwara M, Harris AL, Toi M. High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer. British Journal of Cancer. PMID 31819188 DOI: 10.1038/s41416-019-0662-8 |
0.516 |
|
| 2019 |
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. Breast Cancer (Tokyo, Japan). PMID 31811519 DOI: 10.1007/s12282-019-01029-3 |
0.328 |
|
| 2019 |
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. Jama Oncology. PMID 31563959 DOI: 10.1001/jamaoncol.2019.4782 |
0.376 |
|
| 2019 |
Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. PMID 31318460 DOI: 10.1002/cncr.32392 |
0.362 |
|
| 2019 |
Tanaka S, Senda N, Iida A, Sehara-Fujisawa A, Ishii T, Sato F, Toi M, Itou J. In silico analysis-based identification of the target residue of integrin α6 for metastasis inhibition of basal-like breast cancer. Genes to Cells : Devoted to Molecular & Cellular Mechanisms. PMID 31295752 DOI: 10.1111/gtc.12714 |
0.334 |
|
| 2019 |
Ono Y, Yoshimura M, Hirata K, Yamauchi C, Toi M, Suzuki E, Takada M, Hiraoka M, Mizowaki T. The impact of age on the risk of ipsilateral breast tumor recurrence after breast-conserving therapy in breast cancer patients with a > 5 mm margin treated without boost irradiation. Radiation Oncology (London, England). 14: 121. PMID 31291997 DOI: 10.1186/s13014-019-1327-8 |
0.353 |
|
| 2019 |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Bmc Cancer. 19: 620. PMID 31234810 DOI: 10.1186/s12885-019-5831-x |
0.345 |
|
| 2019 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 31168692 DOI: 10.1007/s12282-019-00984-1 |
0.416 |
|
| 2019 |
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. Bmc Cancer. 19: 517. PMID 31146717 DOI: 10.1186/s12885-019-5687-0 |
0.332 |
|
| 2019 |
Masuda N, Mukai H, Inoue K, Rai Y, Ohno S, Mori Y, Hashigaki S, Muramatsu Y, Umeyama Y, Iwata H, Toi M. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer. Breast Cancer (Tokyo, Japan). PMID 31127500 DOI: 10.1007/s12282-019-00970-7 |
0.348 |
|
| 2019 |
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, ... Toi M, et al. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. Journal of Global Oncology. 1-19. PMID 31125276 DOI: 10.1200/JGO.18.00173 |
0.416 |
|
| 2019 |
Sakaguchi R, Kataoka M, Kanao S, Miyake KK, Nakamoto Y, Sugie T, Toi M, Mikami Y, Togashi K. Distribution pattern of FDG uptake using ring-type dedicated breast PET in comparison to whole-body PET/CT scanning in invasive breast cancer. Annals of Nuclear Medicine. PMID 31115856 DOI: 10.1007/s12149-019-01364-7 |
0.342 |
|
| 2019 |
Yap YS, Lu YS, Tamura K, Lee JE, Ko EY, Park YH, Cao AY, Lin CH, Toi M, Wu J, Lee SC. Insights Into Breast Cancer in the East vs the West: A Review. Jama Oncology. PMID 31095268 DOI: 10.1001/jamaoncol.2019.0620 |
0.428 |
|
| 2019 |
Takada M, Toi M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. International Journal of Clinical Oncology. 24: 608-613. PMID 30982153 DOI: 10.1007/s10147-019-01448-4 |
0.481 |
|
| 2019 |
Ueno T, Saji S, Masuda N, Iwata H, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Sasano H, Toi M. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. Esmo Open. 4: e000476. PMID 30962956 DOI: 10.1136/esmoopen-2018-000476 |
0.397 |
|
| 2019 |
Benson JR, Jatoi I, Toi M. Surgical management of multiple ipsilateral breast cancers. Future Oncology (London, England). PMID 30924355 DOI: 10.2217/fon-2019-0028 |
0.425 |
|
| 2019 |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Saji S, Imoto S, Sasano H, Toi M. Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. International Journal of Molecular Sciences. 20. PMID 30813476 DOI: 10.3390/ijms20040984 |
0.311 |
|
| 2019 |
Kikawa Y, Kotake T, Kajiwara Y, Hashimoto K, Yamashiro H, Ohtani S, Takao S, Toi M. Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan. Breast Cancer : Basic and Clinical Research. 13: 1178223418825135. PMID 30733627 DOI: 10.1177/1178223418825135 |
0.426 |
|
| 2018 |
Ueno T, Saji S, Chiba T, Kamma H, Isaka H, Itoh H, Imi K, Miyamoto K, Tada M, Sasano H, Toi M, Imoto S. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 40: 1010428318811025. PMID 30841783 DOI: 10.1177/1010428318811025 |
0.321 |
|
| 2018 |
Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M. Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. Oncotarget. 9: 37216-37228. PMID 30647855 DOI: 10.18632/oncotarget.26469 |
0.364 |
|
| 2018 |
Shiina T, Toi M, Yagi T. Development and clinical translation of photoacoustic mammography. Biomedical Engineering Letters. 8: 157-165. PMID 30603200 DOI: 10.1007/s13534-018-0070-7 |
0.358 |
|
| 2018 |
Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, Yamamoto Y, Nishimura R, Sato N, Ohsumi S, Iwata H, Mori Y, Hashigaki S, Muramatsu Y, Nagasawa T, ... ... Toi M, et al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. International Journal of Clinical Oncology. PMID 30515674 DOI: 10.1007/s10147-018-1353-9 |
0.33 |
|
| 2018 |
Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proceedings of the National Academy of Sciences of the United States of America. PMID 30352856 DOI: 10.1073/Pnas.1803177115 |
0.371 |
|
| 2018 |
Suzuki E, Sugimoto M, Kawaguchi K, Pu F, Uozumi R, Yamaguchi A, Nishie M, Tsuda M, Kotake T, Morita S, Toi M. Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients. Breast Cancer (Tokyo, Japan). PMID 30317464 DOI: 10.1007/s12282-018-0920-2 |
0.37 |
|
| 2018 |
Takada M, Sugimoto M, Masuda N, Iwata H, Kuroi K, Yamashiro H, Ohno S, Ishiguro H, Inamoto T, Toi M. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Research and Treatment. 172: 611-618. PMID 30194511 DOI: 10.1007/s10549-018-4958-9 |
0.393 |
|
| 2018 |
Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, Saji S, Takano T, ... ... Toi M, et al. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Japanese Journal of Clinical Oncology. PMID 30020510 DOI: 10.1093/jjco/hyy097 |
0.361 |
|
| 2018 |
Yamashiro H, Sawaki M, Masuda N, Okumura Y, Takano T, Tokunaga E, Saito T, Sagara Y, Yamazaki K, Kawaguchi Y, Lee T, Ozaki S, Yamagami K, Yamamoto N, Kuroi K, ... ... Toi M, et al. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study. Breast Cancer : Basic and Clinical Research. 12: 1178223418786243. PMID 30013356 DOI: 10.1177/1178223418786243 |
0.428 |
|
| 2018 |
Yamaga I, Kawaguchi-Sakita N, Asao Y, Matsumoto Y, Yoshikawa A, Fukui T, Takada M, Kataoka M, Kawashima M, Fakhrejahani E, Kanao S, Nakayama Y, Tokiwa M, Torii M, Yagi T, ... ... Toi M, et al. Vascular branching point counts using photoacoustic imaging in the superficial layer of the breast: A potential biomarker for breast cancer. Photoacoustics. 11: 6-13. PMID 30003041 DOI: 10.1016/j.pacs.2018.06.002 |
0.483 |
|
| 2018 |
Kiso M, Tanaka S, Saji S, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. International Journal of Cancer. PMID 29971782 DOI: 10.1002/ijc.31645 |
0.395 |
|
| 2018 |
Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, Kosaka Y, Hattori M, Yamashita T, Takao S, Sato N, Iwata H, Kurosumi M, Toi M. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Research and Treatment. PMID 29971625 DOI: 10.1007/s10549-018-4873-0 |
0.487 |
|
| 2018 |
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine. PMID 29905023 DOI: 10.1002/cam4.1600 |
0.368 |
|
| 2018 |
Ueno T, Masuda N, Kamigaki S, Morimoto T, Akiyama F, Kurosumi M, Tsuda H, Mikami Y, Tanaka S, Morita S, Toi M. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Medicine. PMID 29733541 DOI: 10.1002/cam4.1516 |
0.379 |
|
| 2018 |
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute. PMID 29659933 DOI: 10.1093/Jnci/Djy018 |
0.599 |
|
| 2018 |
Miyake O, Murata K, Tanaka S, Ishiguro H, Toi M, Tamura K, Kawakami K. Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial. Japanese Journal of Clinical Oncology. 48: 410-416. PMID 29590407 DOI: 10.1093/jjco/hyy030 |
0.381 |
|
| 2018 |
Ueno T, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. Esmo Open. 3: e000314. PMID 29531841 DOI: 10.1136/esmoopen-2017-000314 |
0.354 |
|
| 2018 |
Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, et al. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 3079-3086. PMID 29530933 DOI: 10.1158/1078-0432.CCR-17-3473 |
0.306 |
|
| 2018 |
Kotake T, Toi M. Abemaciclib for the treatment of breast cancer. Expert Opinion On Pharmacotherapy. 19: 517-524. PMID 29522364 DOI: 10.1080/14656566.2018.1448787 |
0.461 |
|
| 2018 |
Itou J, Li W, Ito S, Tanaka S, Matsumoto Y, Sato F, Toi M. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif containing 21. The Journal of Biological Chemistry. PMID 29511085 DOI: 10.1074/jbc.RA117.000245 |
0.433 |
|
| 2018 |
Förnvik D, Kataoka M, Iima M, Ohashi A, Kanao S, Toi M, Togashi K. The role of breast tomosynthesis in a predominantly dense breast population at a tertiary breast centre: breast density assessment and diagnostic performance in comparison with MRI. European Radiology. 28: 3194-3203. PMID 29460074 DOI: 10.1007/s00330-017-5297-7 |
0.401 |
|
| 2018 |
Miyake KK, Nakamoto Y, Saji S, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K. Impact of physiological hormonal fluctuations on F-fluorodeoxyglucose uptake in breast cancer. Breast Cancer Research and Treatment. 169: 437-446. PMID 29423901 DOI: 10.1007/s10549-018-4711-4 |
0.32 |
|
| 2018 |
Itou J, Tsukihara H, Nukatsuka M, Toi M, Takechi T. 5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation. Cancer Medicine. 7: 463-470. PMID 29356434 DOI: 10.1002/cam4.1265 |
0.316 |
|
| 2018 |
Matsumoto Y, Itou J, Sato F, Toi M. SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. Cancer Medicine. PMID 29356399 DOI: 10.1002/cam4.1296 |
0.404 |
|
| 2018 |
Sugie T, Suzuki E, Yamauchi A, Yamagami K, Masuda N, Gondo N, Sumi E, Ikeda T, Tada H, Uozumi R, Kanao S, Tanaka Y, Hamazaki Y, Minato N, Toi M. Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. Breast (Edinburgh, Scotland). 38: 114-119. PMID 29310035 DOI: 10.1016/j.breast.2017.12.017 |
0.483 |
|
| 2017 |
Tanaka S, Ueno T, Ishiguro H, Morita S, Toi M. The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. Npj Precision Oncology. 1: 6. PMID 29872695 DOI: 10.1038/s41698-017-0006-1 |
0.332 |
|
| 2017 |
Toi M, Masuda N, Lee SJ. Capecitabine for primary breast cancer. Oncotarget. 8: 110739-110740. PMID 29340011 DOI: 10.18632/oncotarget.22990 |
0.502 |
|
| 2017 |
Chow LW, Morita S, Chow CY, Ng WK, Toi M. Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict value. Endocrine-Related Cancer. PMID 29158285 DOI: 10.1530/ERC-17-0396 |
0.308 |
|
| 2017 |
Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, ... ... Toi M, et al. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study. Current Medical Research and Opinion. 1-16. PMID 29095648 DOI: 10.1080/03007995.2017.1400426 |
0.332 |
|
| 2017 |
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017756155. PMID 28968163 DOI: 10.1200/JCO.2017.75.6155 |
0.343 |
|
| 2017 |
Sagara Y, Julia W, Golshan M, Toi M. Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma of Breast. Frontiers in Oncology. 7: 192. PMID 28894698 DOI: 10.3389/fonc.2017.00192 |
0.402 |
|
| 2017 |
Toi M, Masuda N, Ohashi Y. Adjuvant Capecitabine for Breast Cancer. The New England Journal of Medicine. 377: 791-2. PMID 28834474 DOI: 10.1056/NEJMc1708487 |
0.513 |
|
| 2017 |
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, ... ... Toi M, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England Journal of Medicine. 376: 2147-2159. PMID 28564564 DOI: 10.1056/NEJMoa1612645 |
0.36 |
|
| 2017 |
Onishi N, Kataoka M, Kanao S, Sagawa H, Iima M, Nickel MD, Toi M, Togashi K. Ultrafast dynamic contrast-enhanced mri of the breast using compressed sensing: breast cancer diagnosis based on separate visualization of breast arteries and veins. Journal of Magnetic Resonance Imaging : Jmri. 47: 97-104. PMID 28556576 DOI: 10.1002/jmri.25747 |
0.409 |
|
| 2017 |
Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, et al. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Research : Bcr. 19: 47. PMID 28399902 DOI: 10.1186/s13058-017-0839-0 |
0.398 |
|
| 2017 |
Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016697722. PMID 28375706 DOI: 10.1200/JCO.2016.69.7722 |
0.304 |
|
| 2016 |
Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, Saji S, Toi M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. Breast Cancer Research : Bcr. 18: 129. PMID 27993161 DOI: 10.1186/s13058-016-0788-z |
0.392 |
|
| 2016 |
Itou J, Tanaka S, Li W, Iida A, Sehara-Fujisawa A, Sato F, Toi M. The Sal-like 4 - integrin α6β1 network promotes cell migration for metastasis via activation of focal adhesion dynamics in basal-like breast cancer cells. Biochimica Et Biophysica Acta. PMID 27773610 DOI: 10.1016/j.bbamcr.2016.10.012 |
0.308 |
|
| 2016 |
Benson JR, Jatoi I, Toi M. Treatment of low-risk ductal carcinoma in situ: is nothing better than something? The Lancet. Oncology. 17: e442-e451. PMID 27733270 DOI: 10.1016/S1470-2045(16)30367-9 |
0.33 |
|
| 2016 |
Hirata K, Yoshimura M, Inoue M, Yamauchi C, Ogura M, Toi M, Suzuki E, Takeuchi M, Takada M, Hiraoka M. Regional recurrence in breast cancer patients with one to three positive axillary lymph nodes treated with breast-conserving surgery and whole breast irradiation. Journal of Radiation Research. PMID 27422931 DOI: 10.1093/jrr/rrw071 |
0.423 |
|
| 2016 |
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, et al. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27091708 DOI: 10.1200/JCO.2015.63.9161 |
0.432 |
|
| 2016 |
Shi G, Yoshida Y, Yuki K, Nishimura T, Kawata Y, Kawashima M, Iwaisako K, Yoshikawa K, Kurebayashi J, Toi M, Noda M. Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity. Oncotarget. PMID 27058625 DOI: 10.18632/oncotarget.8620 |
0.412 |
|
| 2016 |
Li W, Itou J, Tanaka S, Nishimura T, Sato F, Toi M. A homeobox protein, NKX6.1, up-regulates interleukin-6 expression for cell growth in basal-like breast cancer cells. Experimental Cell Research. PMID 27032575 DOI: 10.1016/j.yexcr.2016.03.023 |
0.395 |
|
| 2016 |
Ueno T, Saji S, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, ... Toi M, et al. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. Bmc Cancer. 16: 230. PMID 26984766 DOI: 10.1186/s12885-016-2270-9 |
0.446 |
|
| 2016 |
Kawaguchi K, Suzuki E, Yamaguchi A, Yamamoto M, Morita S, Toi M. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer (Tokyo, Japan). 24: 111-120. PMID 26942414 DOI: 10.1007/s12282-016-0682-7 |
0.412 |
|
| 2015 |
Itou J, Tanaka S, Li W, Matsumoto Y, Sato F, Toi M. Data of a fluorescent imaging-based analysis of anti-cancer drug effects on three-dimensional cultures of breast cancer cells. Data in Brief. 5: 429-33. PMID 26958605 DOI: 10.1016/j.dib.2015.09.037 |
0.394 |
|
| 2015 |
Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, Kajihara S, Fujita Y, Iwamoto S, Tanaka K, Toi M. Serum immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochemical and Biophysical Research Communications. PMID 26740182 DOI: 10.1016/J.Bbrc.2015.12.114 |
0.321 |
|
| 2015 |
Fakhrejahani E, Torii M, Kitai T, Kanao S, Asao Y, Hashizume Y, Mikami Y, Yamaga I, Kataoka M, Sugie T, Takada M, Haga H, Togashi K, Shiina T, Toi M. Clinical Report on the First Prototype of a Photoacoustic Tomography System with Dual Illumination for Breast Cancer Imaging. Plos One. 10: e0139113. PMID 26506106 DOI: 10.1371/journal.pone.0139113 |
0.388 |
|
| 2015 |
Sato F, Toi M. [Molecular targeted therapy and genomic evolution of breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 73: 1364-72. PMID 26281691 |
0.427 |
|
| 2015 |
Sugie T, Kinoshita T, Masuda N, Sawada T, Yamauchi A, Kuroi K, Taguchi T, Bando H, Yamashiro H, Lee T, Shinkura N, Kato H, Ikeda T, Yoshimura K, Ueyama H, ... Toi M, et al. Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer. Annals of Surgical Oncology. PMID 26275781 DOI: 10.1245/s10434-015-4809-4 |
0.315 |
|
| 2015 |
Ueno T, Utsumi J, Toi M, Shimizu K. Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. Biomed Research International. 2015: 960840. PMID 26171396 DOI: 10.1155/2015/960840 |
0.43 |
|
| 2015 |
Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. The Lancet. Oncology. 16: 816-29. PMID 26092818 DOI: 10.1016/S1470-2045(15)00051-0 |
0.403 |
|
| 2015 |
Sato F, Saji S, Toi M. Genomic tumor evolution of breast cancer. Breast Cancer (Tokyo, Japan). PMID 25998191 DOI: 10.1007/s12282-015-0617-8 |
0.371 |
|
| 2015 |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, et al. Personalization of loco-regional care for primary breast cancer patients (part 2). Future Oncology (London, England). 11: 1301-5. PMID 25952778 DOI: 10.2217/fon.15.66 |
0.435 |
|
| 2015 |
Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, et al. Personalization of loco-regional care for primary breast cancer patients (part 1). Future Oncology (London, England). 11: 1297-300. PMID 25952777 DOI: 10.2217/fon.15.65 |
0.414 |
|
| 2015 |
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, ... ... Toi M, et al. Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients. International Journal of Clinical Oncology. PMID 25772578 DOI: 10.1007/S10147-015-0814-7 |
0.424 |
|
| 2015 |
Yamshiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Ohno S, Kuroi K, ... ... Toi M, et al. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients. International Journal of Clinical Oncology. PMID 25666483 DOI: 10.1007/s10147-015-0785-8 |
0.408 |
|
| 2015 |
Suzuki E, Kataoka TR, Hirata M, Kawaguchi K, Nishie M, Haga H, Toi M. Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. Bmc Cancer. 15: 39. PMID 25655677 DOI: 10.1186/s12885-015-1041-3 |
0.428 |
|
| 2015 |
Mukai H, Noguchi S, Akiyama F, Inaji H, Iwase H, Horiguchi J, Kurebayashi J, Hirata K, Toi M, Kurosumi M, Kohno N, Nishimura R, Nakamura S, Imoto S, Iwase T, et al. 2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission. Breast Cancer (Tokyo, Japan). 22: 1-4. PMID 25056934 DOI: 10.1007/s12282-014-0550-2 |
0.373 |
|
| 2014 |
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. Journal of Translational Medicine. 12: 310. PMID 25421542 DOI: 10.1186/s12967-014-0310-2 |
0.451 |
|
| 2014 |
Sugimoto M, Takada M, Toi M. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients. The International Journal of Biological Markers. 29: e372-9. PMID 25096734 DOI: 10.5301/jbm.5000103 |
0.336 |
|
| 2014 |
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology. 15: 580-91. PMID 24742739 DOI: 10.1016/S1470-2045(14)70138-X |
0.305 |
|
| 2014 |
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer (Tokyo, Japan). PMID 24574277 DOI: 10.1007/s12282-014-0524-4 |
0.435 |
|
| 2014 |
Fakhrejahani E, Toi M. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Japanese Journal of Clinical Oncology. 44: 197-207. PMID 24474817 DOI: 10.1093/jjco/hyt201 |
0.421 |
|
| 2014 |
Yamashiro H, Takada M, Nakatani E, Imai S, Yamauchi A, Tsuyuki S, Matsutani Y, Sakata S, Wada Y, Okamura R, Harada T, Tanaka F, Moriguchi Y, Kato H, Higashide S, ... ... Toi M, et al. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan. International Journal of Clinical Oncology. 19: 852-62. PMID 24292334 DOI: 10.1007/s10147-013-0643-5 |
0.379 |
|
| 2014 |
Ueno T, Masuda N, Yamanaka T, Saji S, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology. 19: 607-13. PMID 24101215 DOI: 10.1007/s10147-013-0614-x |
0.396 |
|
| 2014 |
Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, Ito Y, Aogi K, Takatsuka Y, Arioka H. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer (Tokyo, Japan). 21: 20-7. PMID 22382811 DOI: 10.1007/s12282-012-0344-3 |
0.311 |
|
| 2014 |
Takuwa H, Ueno T, Ishiguro H, Mikami Y, Kanao S, Takada M, Sugie T, Toi M. A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy Breast Cancer. 21: 504-507. PMID 21526425 DOI: 10.1007/s12282-011-0269-2 |
0.455 |
|
| 2013 |
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata H, Masuda N, Sato N, Tsuda H, Kurosumi M, Akiyama F. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer (Tokyo, Japan). PMID 24338638 DOI: 10.1007/s12282-013-0511-1 |
0.437 |
|
| 2013 |
Sugimoto M, Takada M, Toi M. Comparison of robustness against missing values of alternative decision tree and multiple logistic regression for predicting clinical data in primary breast cancer. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2013: 3054-7. PMID 24110372 DOI: 10.1109/EMBC.2013.6610185 |
0.35 |
|
| 2013 |
Kaga C, Takagi A, Kano M, Kado S, Kato I, Sakai M, Miyazaki K, Nanno M, Ishikawa F, Ohashi Y, Toi M. Lactobacillus casei Shirota enhances the preventive efficacy of soymilk in chemically induced breast cancer. Cancer Science. 104: 1508-14. PMID 23992486 DOI: 10.1111/cas.12268 |
0.37 |
|
| 2013 |
Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S, Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y. Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study. Current Nutrition and Food Science. 9: 194-200. PMID 23966890 DOI: 10.2174/15734013113099990001 |
0.479 |
|
| 2013 |
Itou J, Matsumoto Y, Yoshikawa K, Toi M. Sal-like 4 (SALL4) suppresses CDH1 expression and maintains cell dispersion in basal-like breast cancer. Febs Letters. 587: 3115-21. PMID 23954296 DOI: 10.1016/j.febslet.2013.07.049 |
0.439 |
|
| 2013 |
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. The Lancet. Oncology. 14: 933-42. PMID 23932548 DOI: 10.1016/S1470-2045(13)70335-8 |
0.458 |
|
| 2013 |
Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. Cancer Science. 104: 1539-43. PMID 23905924 DOI: 10.1111/cas.12245 |
0.476 |
|
| 2013 |
Horvath A, Pakala SB, Mudvari P, Reddy SD, Ohshiro K, Casimiro S, Pires R, Fuqua SA, Toi M, Costa L, Nair SS, Sukumar S, Kumar R. Novel insights into breast cancer genetic variance through RNA sequencing. Scientific Reports. 3: 2256. PMID 23884293 DOI: 10.1038/Srep02256 |
0.432 |
|
| 2013 |
Kawashima M, Iwamoto N, Kawaguchi-Sakita N, Sugimoto M, Ueno T, Mikami Y, Terasawa K, Sato TA, Tanaka K, Shimizu K, Toi M. High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer. Cancer Science. 104: 1372-9. PMID 23837649 DOI: 10.1111/cas.12229 |
0.444 |
|
| 2013 |
Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. International Journal of Clinical Oncology. 19: 452-9. PMID 23739924 DOI: 10.1007/s10147-013-0570-5 |
0.364 |
|
| 2013 |
Komuro M, Suzuki K, Kanebako M, Kawahara T, Otoi T, Kitazato K, Inagi T, Makino K, Toi M, Terada H. Novel iontophoretic administration method for local therapy of breast cancer. Journal of Controlled Release : Official Journal of the Controlled Release Society. 168: 298-306. PMID 23562634 DOI: 10.1016/j.jconrel.2013.03.021 |
0.327 |
|
| 2013 |
Ishiguro H, Saji S, Toi M. [Clinical pharmacology of targeted drug for breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 443-6. PMID 23513881 |
0.393 |
|
| 2013 |
Ohno S, Kuroi K, Toi M. An overview of the Japan Breast Cancer Research Group (JBCRG) activities. Breast Cancer (Tokyo, Japan). 20: 291-5. PMID 23494592 DOI: 10.1007/s12282-012-0420-8 |
0.451 |
|
| 2013 |
Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opinion On Investigational Drugs. 22: 299-307. PMID 23394482 DOI: 10.1517/13543784.2013.766715 |
0.319 |
|
| 2013 |
Masuda N, Toi M, Kuroi K. [Current activities and perspective of JBCRG (Japan Breast Cancer Research Group)]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 763-72. PMID 23350501 |
0.407 |
|
| 2013 |
Kitai T, Toi M. [Photoacoustic mammography for the diagnosis of breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 326-30. PMID 23350415 |
0.492 |
|
| 2013 |
Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, Minato N, Toi M, Tanaka Y. Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunology, Immunotherapy : Cii. 62: 677-87. PMID 23151944 DOI: 10.1007/S00262-012-1368-4 |
0.374 |
|
| 2013 |
Suzuki Y, Saeki T, Aogi K, Toi M, Fujii H, Inoue K, Watanabe T, Fujiwara Y, Ito Y, Takatsuka Y, Iwata H, Arioka H, Tokuda Y. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International Journal of Clinical Oncology. 18: 590-7. PMID 22585426 DOI: 10.1007/s10147-012-0421-9 |
0.38 |
|
| 2012 |
Chan MS, Wang L, Felizola SJ, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. The International Journal of Biological Markers. 27: e295-304. PMID 23280127 DOI: 10.5301/JBM.2012.10439 |
0.315 |
|
| 2012 |
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, et al. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research and Treatment. 136: 919-26. PMID 23143284 DOI: 10.1007/s10549-012-2333-9 |
0.363 |
|
| 2012 |
Suzuki R, Saji S, Toi M. Impact of body mass index on breast cancer in accordance with the life-stage of women. Frontiers in Oncology. 2: 123. PMID 23061041 DOI: 10.3389/fonc.2012.00123 |
0.428 |
|
| 2012 |
Takeuchi M, Sugie T, Abdelazeem K, Kato H, Shinkura N, Takada M, Yamashiro H, Ueno T, Toi M. Lymphatic mapping with fluorescence navigation using indocyanine green and axillary surgery in patients with primary breast cancer. The Breast Journal. 18: 535-41. PMID 23009222 DOI: 10.1111/tbj.12004 |
0.364 |
|
| 2012 |
Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y, Toi M, Togashi K. Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1534-42. PMID 22933819 DOI: 10.2967/jnumed.111.100958 |
0.423 |
|
| 2012 |
Kitai T, Torii M, Sugie T, Kanao S, Mikami Y, Shiina T, Toi M. Photoacoustic mammography: initial clinical results. Breast Cancer (Tokyo, Japan). 21: 146-53. PMID 22484692 DOI: 10.1007/s12282-012-0363-0 |
0.318 |
|
| 2012 |
Tsuji W, Teramukai S, Ueno M, Toi M, Inamoto T. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer (Tokyo, Japan). 21: 86-95. PMID 22477265 DOI: 10.1007/s12282-012-0358-x |
0.409 |
|
| 2012 |
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. Plos One. 7: e31422. PMID 22384020 DOI: 10.1371/journal.pone.0031422 |
0.357 |
|
| 2012 |
Toi M. [Breast and endocrine tumor-recent progress and future view for treatment of breast cancer-]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 38: 2558. PMID 22315737 |
0.474 |
|
| 2012 |
Ueno T, Emi M, Sato H, Ito N, Muta M, Kuroi K, Toi M. Genome-wide copy number analysis in primary breast cancer. Expert Opinion On Therapeutic Targets. 16: S31-5. PMID 22313367 DOI: 10.1517/14728222.2011.636739 |
0.405 |
|
| 2012 |
Chan MS, Wang L, Chanplakorn N, Tamaki K, Ueno T, Toi M, Loo WT, Chow LW, Suzuki T, Sasano H. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opinion On Therapeutic Targets. 16: S69-78. PMID 22309693 DOI: 10.1517/14728222.2011.628938 |
0.441 |
|
| 2012 |
Takeda K, Kanao S, Okada T, Kataoka M, Ueno T, Toi M, Ishiguro H, Mikami Y, Togashi K. Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy. European Journal of Radiology. 81: 2627-31. PMID 22221829 DOI: 10.1016/j.ejrad.2011.12.013 |
0.4 |
|
| 2012 |
Takada M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Ueno T, Sasano H, Toi M. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast (Edinburgh, Scotland). 21: 40-5. PMID 21855342 DOI: 10.1016/j.breast.2011.07.015 |
0.39 |
|
| 2011 |
Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. European Journal of Cancer (Oxford, England : 1990). 47: 2537-45. PMID 21741825 DOI: 10.1016/j.ejca.2011.06.027 |
0.427 |
|
| 2011 |
Ali AM, Ueno T, Tanaka S, Takada M, Ishiguro H, Abdellah AZ, Toi M. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. European Journal of Cancer (Oxford, England : 1990). 47: 2265-72. PMID 21737256 DOI: 10.1016/j.ejca.2011.06.015 |
0.469 |
|
| 2011 |
Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Japanese Journal of Clinical Oncology. 41: 867-75. PMID 21719750 DOI: 10.1093/jjco/hyr081 |
0.315 |
|
| 2011 |
Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, Wakasa T, Shintaku M, Tsuyuki S, Inamoto T, Toi M. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Science. 102: 1590-6. PMID 21585620 DOI: 10.1111/j.1349-7006.2011.01985.x |
0.402 |
|
| 2011 |
Toi M, Yasui W, Ito H, Tahara E. Recent progress in carcinogenesis, progression and therapy of breast cancer: the 20th Hiroshima Cancer Seminar--the 4th Three Universities' Consortium International Symposium, October 2010: 31 October 2010, International Conference Center Hiroshima. Japanese Journal of Clinical Oncology. 41: 924-30. PMID 21565925 DOI: 10.1093/jjco/hyr054 |
0.449 |
|
| 2011 |
Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Annals of Surgical Oncology. 18: 2885-92. PMID 21431404 DOI: 10.1245/s10434-011-1666-7 |
0.318 |
|
| 2011 |
Takada M, Toi M. [Surgery for breast cancer -- from radical mastectomy to breast-conserving surgery]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 38: 173-8. PMID 21368479 |
0.444 |
|
| 2011 |
Honda M, Saji S, Horiguchi S, Suzuki E, Aruga T, Horiguchi K, Kitagawa D, Sekine S, Funata N, Toi M, Kuroi K. Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast. Surgery Today. 41: 328-32. PMID 21365411 DOI: 10.1007/s00595-009-4276-2 |
0.377 |
|
| 2011 |
Toi M. [Current organ topics: chemotherapy of breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 37: 2844. PMID 21235089 |
0.453 |
|
| 2011 |
Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Science. 102: 858-65. PMID 21231986 DOI: 10.1111/j.1349-7006.2011.01867.x |
0.44 |
|
| 2011 |
Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Research and Treatment. 127: 739-49. PMID 21082239 DOI: 10.1007/s10549-010-1243-y |
0.308 |
|
| 2010 |
Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. Journal of Medical and Dental Sciences. 57: 155-63. PMID 21073134 |
0.455 |
|
| 2010 |
Yamashiro H, Toi M. [Molecular targeted therapy for breast cancer treatment, challenge to cure]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 68: 1854-8. PMID 20954329 |
0.411 |
|
| 2010 |
Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW, Toi M, Sasano H. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Anticancer Research. 30: 3465-72. PMID 20944124 |
0.378 |
|
| 2010 |
Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno E, Ishiguro H, Bando H. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Japanese Journal of Clinical Oncology. 40: i13-18. PMID 20870914 DOI: 10.1093/jjco/hyq122 |
0.508 |
|
| 2010 |
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemotherapy and Pharmacology. 67: 1007-15. PMID 20628744 DOI: 10.1007/s00280-010-1390-1 |
0.348 |
|
| 2010 |
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 116: 3112-8. PMID 20564629 DOI: 10.1002/cncr.25206 |
0.369 |
|
| 2010 |
Kitagawa D, Saji S, Horiguchi S, Satoh Y, Horiguchi K, Toi M, Funata N, Kuroi K. Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy. The Breast Journal. 16: 435-6. PMID 20545937 DOI: 10.1111/j.1524-4741.2010.00943.x |
0.376 |
|
| 2010 |
Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer (Tokyo, Japan). 18: 64-7. PMID 20354831 DOI: 10.1007/s12282-010-0198-5 |
0.348 |
|
| 2010 |
Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clinical Therapeutics. 32: 311-26. PMID 20206789 DOI: 10.1016/j.clinthera.2010.01.029 |
0.37 |
|
| 2010 |
Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. Bmc Cancer. 10: 56. PMID 20178580 DOI: 10.1186/1471-2407-10-56 |
0.373 |
|
| 2010 |
Sugie T, Tanaka Y, Toi M. [New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 2555-9. PMID 20104681 |
0.498 |
|
| 2010 |
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer (Tokyo, Japan). 17: 190-8. PMID 19575284 DOI: 10.1007/s12282-009-0132-x |
0.33 |
|
| 2009 |
Kondo M, Hoshi SL, Toi M. Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Japanese Journal of Clinical Oncology. 39: 767-70. PMID 19656807 DOI: 10.1093/jjco/hyp081 |
0.364 |
|
| 2009 |
Aruga T, Suzuki E, Saji S, Horiguchi S, Horiguchi K, Sekine S, Kitagawa D, Funata N, Toi M, Sugihara K, Kuroi K. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncology Reports. 22: 273-8. PMID 19578766 |
0.38 |
|
| 2009 |
Toi M, Sasano H, Ellis MJ. [Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 36: 1035-42. PMID 19542732 |
0.435 |
|
| 2009 |
Noguchi S, Toi M. From standardization to personalization in breast cancer treatment. Breast Cancer (Tokyo, Japan). 16: 241-2. PMID 19350355 DOI: 10.1007/s12282-009-0106-z |
0.459 |
|
| 2009 |
Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 63: 703-6. PMID 19269774 DOI: 10.1016/j.biopha.2009.02.003 |
0.422 |
|
| 2009 |
Toi M, Yamashiro H, Tsuji W. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer. Breast Cancer (Tokyo, Japan). 16: 207-18. PMID 19259765 DOI: 10.1007/s12282-009-0096-x |
0.431 |
|
| 2009 |
Takada M, Ishiguro H, Toi M. [Treatment for breast cancer and endocrine neoplasm]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 2344-50. PMID 19117102 |
0.488 |
|
| 2009 |
Toi M. [Breast and endocrine tumor]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 2338. PMID 19117100 |
0.361 |
|
| 2008 |
Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, Kato H, Toi M, Fukushima M. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. Bmc Cancer. 8: 323. PMID 18990247 DOI: 10.1186/1471-2407-8-323 |
0.343 |
|
| 2008 |
Toi M. Novel targeting therapy concept for breast cancer treatment. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 132: 177-9. PMID 18787301 DOI: 10.1254/fpj.132.177 |
0.421 |
|
| 2008 |
Yoshibayashi H, Ishiguro H, Takada M, Takeuchi M, Yamashiro H, Ueno T, Kato H, Yoshikawa K, Kanao S, Yamauchi C, Mikami Y, Toi M. [A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 35: 987-90. PMID 18633230 |
0.462 |
|
| 2008 |
Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. Anti-Cancer Drugs. 19: 753-9. PMID 18594220 DOI: 10.1097/CAD.0b013e328302eb15 |
0.349 |
|
| 2008 |
Yagata H, Nakamura S, Toi M, Bando H, Ohno S, Kataoka A. Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. International Journal of Clinical Oncology. 13: 252-6. PMID 18553236 DOI: 10.1007/s10147-007-0748-9 |
0.398 |
|
| 2008 |
Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 111: 13-7. PMID 18514508 DOI: 10.1016/j.jsbmb.2008.04.004 |
0.442 |
|
| 2008 |
Yamashiro H, Toi M. Update of evidence in chemotherapy for breast cancer. International Journal of Clinical Oncology. 13: 3-7. PMID 18307012 DOI: 10.1007/s10147-007-0719-1 |
0.502 |
|
| 2008 |
Chow LW, Yip AY, Loo WT, Toi M. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Letters. 262: 232-8. PMID 18248884 DOI: 10.1016/j.canlet.2007.12.003 |
0.409 |
|
| 2008 |
Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. Oncology. 72: 330-7. PMID 18187954 DOI: 10.1159/000113062 |
0.424 |
|
| 2008 |
Toi M. Long-term outcomes of aromatase inhibition for breast cancer. The Lancet. Oncology. 9: 8-10. PMID 18177815 DOI: 10.1016/S1470-2045(07)70392-3 |
0.39 |
|
| 2008 |
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Research and Treatment. 110: 531-9. PMID 17879158 DOI: 10.1007/s10549-007-9744-z |
0.32 |
|
| 2007 |
Takada M, Toi M. [Primary systemic chemotherapy for breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 34: 1730-4. PMID 18030005 |
0.417 |
|
| 2007 |
Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, Abe O. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. International Journal of Oncology. 31: 899-906. PMID 17786323 |
0.4 |
|
| 2007 |
Kitagawa D, Toi M. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 396-401. PMID 17682183 |
0.428 |
|
| 2007 |
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3198-206. PMID 17545523 DOI: 10.1158/1078-0432.CCR-07-0009 |
0.426 |
|
| 2007 |
Suzuki E, Toi M. Improving the efficacy of trastuzumab in breast cancer. Cancer Science. 98: 767-71. PMID 17428260 DOI: 10.1111/j.1349-7006.2007.00455.x |
0.462 |
|
| 2006 |
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 411-7. PMID 17179098 DOI: 10.1200/JCO.2006.08.1646 |
0.431 |
|
| 2006 |
Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Research and Treatment. 104: 267-75. PMID 17066321 DOI: 10.1007/s10549-006-9416-4 |
0.345 |
|
| 2006 |
Suzuki T, Toi M, Saji S, Horiguchi K, Aruga T, Suzuki E, Horiguchi S, Funata N, Karasawa K, Kamata N. Early breast cancer. International Journal of Clinical Oncology. 11: 108-19. PMID 16622745 DOI: 10.1007/s10147-006-0564-7 |
0.469 |
|
| 2006 |
Suzuki E, Toi M. [Neoadjuvant Chemotherapy in breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 64: 536-9. PMID 16529046 |
0.443 |
|
| 2006 |
Saeki T, Kimura T, Toi M, Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer (Tokyo, Japan). 13: 49-57. PMID 16518062 DOI: 10.2325/jbcs.13.49 |
0.401 |
|
| 2006 |
Kondo M, Toi M. Cost-effective treatment options in first-line therapy for advanced breast cancer in Japan. Expert Review of Anticancer Therapy. 6: 197-204. PMID 16445372 DOI: 10.1586/14737140.6.2.197 |
0.409 |
|
| 2006 |
Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemotherapy and Pharmacology. 21-6. PMID 16273360 DOI: 10.1007/s00280-005-0107-3 |
0.449 |
|
| 2005 |
Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M, Piccart M, Snyder R, Toi M, Hortobagyi GN. Reducing the global breast cancer burden: the importance of patterns of care research. Clinical Breast Cancer. 6: 412-20. PMID 16381624 DOI: 10.3816/CBC.2005.n.045 |
0.33 |
|
| 2005 |
Saji S, Toi M. Aromatase inhibitors and other novel agents in breast cancer treatment. Expert Opinion On Emerging Drugs. 7: 303-19. PMID 15989553 DOI: 10.1517/14728214.7.2.303 |
0.435 |
|
| 2005 |
Toi M, Saeki T, Aogi K, Sano M, Hatake K, Asaga T, Tokuda Y, Mitsuyama S, Kimura M, Kobayashi T, Tamura M, Tabei T, Shin E, Nishimura R, Ohno S, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Japanese Journal of Clinical Oncology. 35: 310-5. PMID 15930037 DOI: 10.1093/jjco/hyi090 |
0.451 |
|
| 2005 |
Iwata H, Nakamura S, Toi M, Shin E, Masuda N, Ohno S, Takatsuka Y, Hisamatsu K, Yamazaki K, Kusama M, Kaise H, Sato Y, Kuroi K, Akiyama F, Tsuda H, et al. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage Breast carcinoma Breast Cancer. 12: 99-103. PMID 15858439 DOI: 10.2325/jbcs.12.99 |
0.317 |
|
| 2005 |
Toi M, Takebayashi Y, Chow LW. Translational research in breast cancer Breast Cancer. 12: 86-90. PMID 15858437 DOI: 10.2325/jbcs.12.86 |
0.357 |
|
| 2005 |
Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2986-90. PMID 15837752 DOI: 10.1158/1078-0432.CCR-04-2275 |
0.37 |
|
| 2005 |
Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, Toi M. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 24: 4531-9. PMID 15806142 DOI: 10.1038/Sj.Onc.1208646 |
0.347 |
|
| 2005 |
Toi M, Bando H, Chow LW. Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 58: 531-5. PMID 15599986 DOI: 10.1016/j.biopha.2003.12.016 |
0.397 |
|
| 2004 |
Nakanishi C, Yamaguchi T, Iijima T, Saji S, Toi M, Mori T, Miyaki M. Germline mutation of the LKB1/STK11 gene with loss of the normal allele in an aggressive breast cancer of Peutz-Jeghers syndrome. Oncology. 67: 476-9. PMID 15714005 DOI: 10.1159/000082933 |
0.347 |
|
| 2004 |
Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer (Tokyo, Japan). 11: 129-33. PMID 15550858 DOI: 10.1007/BF02968291 |
0.392 |
|
| 2004 |
Yamashiro H, Toyama K, Bando H, Saji S, Toi M. [Trastuzumab treatment for breast cancer]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 62: 1305-11. PMID 15283148 |
0.486 |
|
| 2004 |
Takada M, Kataoka A, Toi M, Bando H, Toyama K, Horiguchi S, Ueno T, Linder S, Saji S, Hayashi Y, Funata N, Kinoshita J, Murakami S, Ohono S. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. International Journal of Oncology. 25: 397-405. PMID 15254737 |
0.4 |
|
| 2004 |
Kawakita M, Hiramatsu K, Sugimoto M, Takahashi K, Toi M. [Clinical usefulness of urinary diacetylpolyamines as novel tumor markers]. Rinsho Byori. the Japanese Journal of Clinical Pathology. 52: 321-7. PMID 15164599 |
0.305 |
|
| 2004 |
Kawakami M, Saji S, Toi M. [Controversies in endocrine therapy for breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 31: 181-7. PMID 14997748 |
0.357 |
|
| 2004 |
Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T, Lansky EP. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis. 6: 121-8. PMID 14739618 DOI: 10.1023/B:AGEN.0000011802.81320.e4 |
0.38 |
|
| 2004 |
Toi M, Takada M, Bando H, Toyama K, Yamashiro H, Horiguchi S, Saji S. Current status of antibody therapy for breast cancer. Breast Cancer (Tokyo, Japan). 11: 10-4. PMID 14718785 DOI: 10.1007/BF02967994 |
0.407 |
|
| 2004 |
Bando H, Toi M, Kitada K, Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 57: 333-40. PMID 14568227 DOI: 10.1016/s0753-3322(03)00098-2 |
0.405 |
|
| 2004 |
Yamamoto Y, Yamashita J, Toi M, Muta M, Nagai S, Hanai N, Furuya A, Osawa Y, Saji S, Ogawa M. Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. Oncology Reports. 10: 791-6. PMID 12792725 |
0.344 |
|
| 2004 |
Toi M, Bando H, Saji S. Decision tree and paradigms of primary breast cancer: changes elicited by preoperative therapy. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 9: RA90-5. PMID 12761467 |
0.334 |
|
| 2003 |
Atiqur Rahman M, Toi M. Anti-angiogenic therapy in breast cancer. Biomedicine & Pharmacotherapy = BioméDecine & PharmacothéRapie. 57: 463-70. PMID 14637390 |
0.412 |
|
| 2003 |
Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. The Journal of Steroid Biochemistry and Molecular Biology. 86: 443-7. PMID 14623542 |
0.436 |
|
| 2003 |
Kuroi K, Toi M. [Male breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 30: 599-605. PMID 12795089 |
0.461 |
|
| 2003 |
Tominaga T, Koyama H, Toge T, Miura S, Sugimachi K, Yamaguchi S, Hirata K, Monden Y, Nomura Y, Toi M, Kimijima I, Noguchi S, Sonoo H, Asaishi K, Ikeda T, et al. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 991-8. PMID 12637462 DOI: 10.1200/JCO.2003.06.014 |
0.418 |
|
| 2003 |
Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Letters. 190: 191-7. PMID 12565174 DOI: 10.1016/s0304-3835(02)00590-6 |
0.35 |
|
| 2003 |
Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer (Tokyo, Japan). 10: 10-4. PMID 12525757 DOI: 10.1007/BF02967619 |
0.347 |
|
| 2002 |
Nakanishi C, Toi M, Saji S, Bando H. [Current indications for mastectomy in patients with breast cancer]. Nihon Geka Gakkai Zasshi. 103: 821-4. PMID 12478859 |
0.387 |
|
| 2002 |
Watanabe T, Sano M, Toi M, Saeki T, Kanda K, Miura S, Inaji H, Sono H, Saeki H, Nishimura R, Fujita Y. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 29: 1211-21. PMID 12146002 |
0.312 |
|
| 2002 |
Tominaga T, Toi M, Ohashi Y, Abe O. Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clinical Breast Cancer. 3: 55-64. PMID 12020396 DOI: 10.3816/cbc.2002.n.012 |
0.348 |
|
| 2002 |
Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Japanese Journal of Cancer Research : Gann. 93: 389-96. PMID 11985788 |
0.409 |
|
| 2002 |
Tominaga T, Toi M, Abe O, Ohashi Y, Uchino J, Hayasaka H, Abe R, Izuo M, Enomoto K, Watanabe H, Yoshida M, Taguchi T, Koyama H, Senoo T, Toge T, et al. The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. International Journal of Oncology. 20: 517-25. PMID 11836563 |
0.401 |
|
| 2002 |
Kuroi K, Tanaka C, Bando H, Saji S, Hayashi K, Toi M. [Efficacy of biweekly paclitaxel therapy in advanced or recurrent breast cancer]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 29: 55-60. PMID 11816478 |
0.33 |
|
| 2002 |
Kanzaki A, Toi M, Neamati N, Miyashita H, Oubu M, Nakayama K, Bando H, Ogawa K, Mutoh M, Mori S, Terada K, Sugiyama T, Fukumoto M, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Japanese Journal of Cancer Research : Gann. 93: 70-7. PMID 11802810 DOI: 10.1111/J.1349-7006.2002.Tb01202.X |
0.341 |
|
| Show low-probability matches. |